Graft-Versus-Host Disease: A Surge of Developments by Riddell, Stanley R & Appelbaum, Frederick R
PLoS Medicine  |  www.plosmedicine.org 1174
Research in Translation
July 2007  |  Volume 4  |  Issue 7  |  e198
Graft-Versus-Host Disease: 
A Surge of Developments 
Stanley R. Riddell, Frederick R. Appelbaum*
Introduction
This year approximately 20,000 
individuals will receive an allogeneic 
hematopoietic cell transplant (HCT) 
as treatment for a malignant, or 
life-threatening non-malignant, 
hematopoietic disease. The process 
of HCT generally begins with 
administration of a preparative regimen 
to eradicate the underlying disease 
and immunosuppress the patient 
in order to prevent rejection of the 
subsequently transfused hematopoietic 
stem cells. Following HCT, donor T 
cells transplanted with or developing 
from the hematopoietic stem cells 
react with cells of the human leukocyte 
antigen (HLA)-matched but genetically 
non-identical host, providing a 
beneﬁ  cial graft-versus-tumor (GVT) 
response but also resulting in possibly 
life-threatening graft-versus-host 
disease (GVHD). The manifestations 
of GVHD vary over its course. Acute 
GVHD usually appears within several 
weeks of HCT and is characterized 
by a diffuse maculopapular rash, 
mucosal inﬂ  ammation causing crampy 
abdominal pain and diarrhea, and 
elevated liver function tests (Figure 
1). GVHD that ﬁ  rst appears or 
persists more than three months after 
allogeneic HCT is termed chronic 
GVHD and resembles a chronic 
autoimmune disorder. Patients 
frequently develop lichen planus 
skin lesions, ocular and oral sicca, 
obliterative bronchiolitis, and hepatic 
abnormalities resembling primary 
biliary sclerosis.
If no immunosuppression is given 
after allogeneic HCT, life-threatening 
or fatal GVHD inevitably develops. The 
ﬁ  rst successful application of allogeneic 
HCT to treat human leukemia in the 
early 1970s was made possible by the 
use of methotrexate, administered early 
after transplantation as prophylaxis 
against GVHD [1]. In the mid-1980s, 
prospective randomized trials were 
performed demonstrating that a 
combination of a calcineurin inhibitor 
(cyclosporin or tacrolimus) plus 
methotrexate was superior to either 
agent alone in preventing acute GVHD 
[2,3], and such combinations remain 
the standard of care today. Despite 
such prophylaxis, approximately 50% 
of patients receiving HCT will develop 
acute GVHD sufﬁ  ciently severe to 
require additional immunosuppression, 
usually in the form of a corticosteroid, 
and approximately 50% of patients 
will develop chronic GVHD requiring 
continued immunosuppression for 
up to several years. The majority of 
patients eventually develop tolerance, 
and immunosuppression can be 
completely withdrawn in these cases, 
but 10%–20% of recipients of HLA-
matched hematopoietic cell transplants 
will die of refractory GVHD or of 
opportunistic infections associated with 
its prevention or treatment, and the 
mortality rate increases with increasing 
donor–recipient HLA disparity.
An elusive goal of research has 
been to ﬁ  nd ways to prevent GVHD 
without dramatically increasing other 
transplant complications. Most clinical 
studies to date have focused on the 
use of alternative immunosuppressants 
or removal of T cells from the donor 
stem cell source. More intensive 
post-transplant immunosuppressive 
regimens and T cell depletion are 
both capable of dramatically reducing 
the incidence and severity of GVHD, 
but do so at the cost of an increased 
incidence of fatal post-transplant 
infections and tumor recurrence. 
Increased graft rejection may also 
occur if donor T cells are removed 
from the donor stem cell graft, because 
the reaction of these cells against 
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Figure 1. Clinical Appearance of Acute Graft-Versus-Host Disease Involving the Skin and the 
Upper Intestinal Mucosa
Left panel: The diffuse erythematous maculopapular rash typical of acute GVHD. Right panel: an 
endoscopic view of the edematous, reddened, friable gastrointestinal mucosa seen in a patient 
with acute GVHD.
Research in Translation discusses health interventions 
in the context of translation from basic to clinical 
research, or from clinical evidence to practice.PLoS Medicine  |  www.plosmedicine.org 1175
residual host immune cells contributes 
to engraftment. More intensive 
preparative regimens can overcome 
this problem but are associated with 
increased toxicity. More potent 
post-transplant immunosuppressive 
regimens and T cell depletion suppress 
or remove immunocompetent cells 
responsible for protection against many 
pathogens as well as cell populations 
that contribute to the beneﬁ  cial GVT 
response. Accordingly, in retrospective 
analyses and prospective randomized 
trials, neither more intensive post-
transplant immunosuppression nor T 
cell depletion has been demonstrated 
to improve survival following allogeneic 
HCT [4]. While it is the case that 
fewer patients succumb to GVHD 
and associated complications today 
than did a decade ago, this is largely 
due to improvements in HLA-typing 
technology and supportive care 
measures rather than advances in the 
direct prevention and treatment of 
GVHD. Recent clinical and animal 
model studies have provided several 
novel and surprising insights into the 
biology of GVHD and provide exciting 
new directions for strategies that may 
prevent GVHD without increasing 
complications.
Haplotype Matching
One area of progress, as noted above, 
has been in HLA-typing technology 
and donor selection. Historically, HLA 
typing was conducted using serologic 
methods, but with the advent of the 
polymerase chain reaction assay in the 
1980s, it became possible to perform 
molecular typing of donor and 
recipient. When patients previously 
transplanted from serologically matched 
donors were retrospectively analyzed 
using molecular typing, approximately 
30% were found to be mismatched with 
the donor for one or more alleles, and 
such mismatching was shown to lead to 
more GVHD and poorer survival [5]. 
Thus, molecular typing of the HLA 
locus has become the standard of care. 
Even with the use of molecular typing 
to identify fully HLA-matched donors, 
unrelated donor transplants continue 
to be associated with more GVHD 
than seen with HLA-matched sibling 
transplants. Using a novel technique 
that allows for the typing of individual 
DNA strands, Petersdorf et al. have 
now shown that among allele-matched 
unrelated donor–recipient pairs, those 
that shared the same physical linkage of 
HLA-A, -B, and -DRB1 were much less 
likely to develop severe GVHD (Figure 
2) [6]. These results imply that other 
unidentiﬁ  ed transplantation antigens 
exist within the same genetic region as 
HLA, and offer a method for improved 
selection among HLA-matched 
unrelated donors.
Genetic Proﬁ  ling
The pathogenesis of GVHD involves the 
expansion and differentiation of donor 
T cells reacting in peripheral lymphoid 
tissues against host antigen-presenting 
cells that display disparate minor 
histocompatibility antigens. These 
antigen-presenting cells are activated as 
a consequence of tissue injury and the 
resulting release of proinﬂ  ammatory 
cytokines [7]. Polymorphisms in 
cytokine genes between donor and 
recipient may inﬂ  uence the host 
inﬂ  ammatory response to tissue 
injury and the severity of GVHD. The 
interleukin-10 (IL-10) pathway is the 
most extensively studied, and speciﬁ  c 
polymorphisms in the recipient IL-
10 promoter region as well as in the 
donor IL-10 receptor beta gene have 
each been found to be associated 
with a lower risk of GVHD and non-
relapse mortality [8,9]. Polymorphisms 
in other immune regulatory genes, 
including those encoding interleukin-6, 
interferon gamma, and tumor necrosis 
factor-alpha, have also been suggested 
to inﬂ  uence the development of GVHD 
[10]. 
In an effort to provide a more global 
assessment of whether a donor is likely 
to induce GVHD, Baron et al. have 
examined gene expression proﬁ  les of 
CD4 and CD8 T cells from donors and 
Five Key Papers in the Field
Ferrara et al., 2006 [7] This review discusses the involvement of cytokine networks and 
links activation of the innate and adaptive immune system with the pathogenesis of 
GVHD.
Wagner et al., 2005 [4] A multicenter randomized trial of T cell depletion versus 
methotrexate and cyclosporine for graft-versus-host disease prophylaxis shows that T 
cell depletion is effective for preventing GVHD but fails to improve survival because of 
increased relapse and infection.
Anderson et al., 2003 [12] Stem cell grafts devoid of naïve T cells but containing 
memory T cells do not cause GVHD and improve immune reconstitution in a murine 
allogeneic hematopoietic cell transplant model.
Dickinson et al., 2002 [22] This paper describes an elegant in situ model of human skin 
GVHD and demonstrates that ubiquitously expressed minor histocompatibility antigens 
are primary targets of GVHD.
Bonnet et al., 1999 [23] The ﬁ  rst direct demonstration that CD8+ minor 
histocompatibility antigen–speciﬁ  c T cells recognize and eliminate human acute 
myeloid leukemia stem cells.
doi:10.1371/journal.pmed.0040198.g002
Figure 2. Schematic Illustration of the HLA Haplotypes of a Patient and 4 HLA Phenotypically 
Identical Potential Donors
Data suggest that the use of the single haplotype-matched donor reduces acute graft-versus-host 
disease.
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report that it is possible to segregate 
donors into those likely to cause GVHD 
and those who are relatively safe [11]. 
If this ability to discriminate between 
strong and weak alloresponders is 
veriﬁ  ed in further studies, these 
ﬁ  ndings could have important 
implications for donor selection.
Donor Graft Manipulation
Stem cell grafts contain distinct 
functional and phenotypic subsets of T 
cells, including antigen-inexperienced 
naïve T cells (TN), antigen-experienced 
memory T cells, (TM), and regulatory 
T cells (TREG). Recent studies have 
begun to dissect the contribution of 
these individual T cell subsets to GVHD 
and have identiﬁ  ed opportunities 
for more reﬁ  ned manipulation of 
the T cell content of stem cell grafts 
that may reduce GVHD without the 
severe T cell deﬁ  ciency associated 
with complete depletion (Figure 3). 
For example, the selective depletion 
of TN from allogeneic stem cell 
grafts abrogated GVHD in both 
CD4- and CD8-dependent multiple 
minor histocompatibility antigen–
mismatched mouse models, and the 
remaining TM provided reconstitution 
of immunity to pathogens [12,13]. 
Human TN and TM can also be 
distinguished based on phenotype—
TN are CD45RA+ and CD62L+, 
while TM are CD45RO+ and either 
CD62L+ or CD62L-, and emerging 
data suggest that alloreactivity for 
minor histocompatibility antigens is 
predominantly contained in the TN 
subset [14]. The human TM repertoire 
comprises less than 1% of the overall 
T cell receptor diversity and consists 
of large numbers of T cells speciﬁ  c 
for cytomegalovirus, Epstein Barr 
virus, and other pathogens that cause 
opportunistic infections in HCT 
recipients [15]. Thus, unless the 
donor has been previously sensitized 
to recipient minor histocompatibility 
antigens (which would convert 
alloreactive naïve T cells to the 
memory pool), transplants using stem 
cells depleted of naïve T cells could 
reduce or eliminate GVHD while 
preserving the transfer of memory T 
cells to common infectious agents. 
Such transplants would overcome a 
major limitation of transplantation 
using complete T cell depletion. The 
recognition that donor CD4+ CD25+ 
Foxp3+ TREG cells suppress T cell 
responses in vitro and in vivo suggests 
another attractive approach to donor 
graft manipulation for preventing 
GVHD. The importance of TREG in 
GVHD is supported by murine studies 
showing that their depletion from stem 
cell grafts exacerbates GVHD and that 
the infusion of additional TREG at the 
time of HCT reduces lethal GVHD, 
apparently by limiting the initial 
activation of alloreactive T cells in 
lymph nodes [16,17]. Clinical studies 
have suggested that stem cell grafts 
from donors with higher numbers of 
TREG confer a lower risk of GVHD [18], 
and efforts are in progress to isolate 
and expand populations of human TREG 
that might be used to supplement stem 
cell grafts and abrogate GVHD [19].
Segregation of GVHD from GVT
Although these new approaches to 
allogeneic HCT are likely to reduce 
the severity of GVHD, an important 
concern for patients undergoing HCT 
for a malignant disease is whether 
reducing GVHD might increase the risk 
of tumor recurrence. Like GVHD, GVT 
is the result of donor T cells reacting 
with disparate minor histocompatibility 
antigens, and elimination of GVHD 
would seem almost certain to diminish 
the GVT effect. Elucidation of the 
molecular structure, HLA restriction, 
and tissue expression of human minor 
histocompatibility antigens, and the 
identiﬁ  cation of non-polymorphic 
leukemia-associated antigens that 
can be recognized by T lymphocytes 
offers the exciting prospect that 
targeted T cell therapy after HCT 
might selectively augment GVT activity 
[20]. An increasing number of minor 
histocompatibility antigens have now 
been molecularly characterized, and 
novel mechanisms of polypeptide 
processing have been uncovered 
[21]. Several minor histocompatibility 
antigens are expressed in both normal 
and malignant hematopoietic cells of 
the recipient, but not in epithelium 
[22]. Thus, donor T cells reactive with 
such tissue-restricted antigens will 
target recipient hematopoietic and 
leukemic cells without damaging non-
hematopoietic tissues or engrafting 
doi:10.1371/journal.pmed.0040198.g003 
Figure 3. Selective Manipulation of T Cell Subsets in Allogeneic Stem Cell Grafts to Reduce 
GVHD while Retaining GVT and Pathogen-Speciﬁ  c Immunity
Strategies being developed to modify the T cell content of allogeneic stem cell grafts include: 
a) depletion of the TN subset of cells that contain the repertoire of T cells capable of recognizing 
minor histocompatibility antigens expressed on skin, gastrointestinal, and hepatic tissues; b) 
expanding TREG cells that interfere with activation of alloreactive T cells to augment the stem cell 
graft; c) isolation and expansion of tumor-reactive T cells from naïve T cell progenitors for adoptive 
immunotherapy to augment the GVT effect; and d) retention of TM cells in the graft to restore 
protective T cell immunity to pathogens.
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donor hematopoietic progenitors. 
Techniques for cloning minor 
histocompatibility antigen–speciﬁ  c T 
cells have been developed, and these 
T cell clones can eliminate primary 
human leukemias in immunodeﬁ  cient 
mice [23]. Pilot studies in which 
cloned donor T cells reactive with 
minor histocompatibility antigens have 
been adoptively transferred to treat 
patients with post-transplant disease 
recurrence have demonstrated the 
principle that GVT and GVHD can 
be segregated based on the tissue 
expression of the target antigen 
[24]. The feasibility of this strategy 
is advancing with reﬁ  nements in the 
culture methods used for isolating 
effector T cells from naïve T cell 
precursors and programming these 
effector cells for GVT activity. The 
identiﬁ  cation of candidate leukemia 
antigens that are not derived from 
polymorphic proteins provides 
additional targets for T cell therapy 
or vaccination that may be broadly 
applied [25]. Thus, strategies to 
abrogate GVHD and its complications 
need not be associated with loss of the 
GVT effect, but may instead employ 
targeted immunotherapy to reduce the 
intensity and duration of post-grafting 
immunosuppression while augmenting 
GVT activity.
Conclusion
The human graft-versus-host reaction 
continues to both fascinate and 
frustrate clinical investigation with 
its lack of predictability, possibly 
lethal toxicity, but potentially life-
saving anti-tumor effects. The ability 
to select optimal donors based on 
improved HLA-typing technologies 
and better understanding of non-HLA 
contributions to immune reactivity 
seems at hand, and should substantially 
reduce the risk of developing severe 
GVHD. Clinical studies of donor graft 
manipulation removing TN subsets, 
retaining TM subsets, and possibly 
supplementing TREG subsets are just 
being initiated. In the long term, 
perhaps the most exciting potential 
lies in the segregation of GVHD from 
the GVT reaction based on increased 
recognition of minor histocompatibility 
antigens exclusively expressed on 
normal versus malignant hematopoietic 
tissues. Whether these new advances 
will lead to the hoped-for clinical 
victories will become apparent in the 
next few years.  
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